Literature DB >> 29301771

Off-the-shelf TCR for graft-versus-leukemia without GVHD.

Frederick L Locke1, Claudio Anasetti1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29301771      PMCID： PMC5755047          DOI： 10.1182/blood-2017-11-812990

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

1.  Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease.

Authors:  P Fontaine; G Roy-Proulx; L Knafo; C Baron; D C Roy; C Perreault
Journal:  Nat Med       Date:  2001-07       Impact factor: 53.440

2.  Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML.

Authors:  Fabiana Perna; Samuel H Berman; Rajesh K Soni; Jorge Mansilla-Soto; Justin Eyquem; Mohamad Hamieh; Ronald C Hendrickson; Cameron W Brennan; Michel Sadelain
Journal:  Cancer Cell       Date:  2017-10-09       Impact factor: 31.743

3.  Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors:  Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal:  N Engl J Med       Date:  2014-11-19       Impact factor: 91.245

Review 4.  Adoptive cell transfer as personalized immunotherapy for human cancer.

Authors:  Steven A Rosenberg; Nicholas P Restifo
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

5.  Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers.

Authors:  D P Granados; A Rodenbrock; J-P Laverdure; C Côté; O Caron-Lizotte; C Carli; H Pearson; V Janelle; C Durette; E Bonneil; D C Roy; J-S Delisle; S Lemieux; P Thibault; C Perreault
Journal:  Leukemia       Date:  2016-02-09       Impact factor: 11.528

6.  Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS.

Authors:  Isao Tawara; Shinichi Kageyama; Yoshihiro Miyahara; Hiroshi Fujiwara; Tetsuya Nishida; Yoshiki Akatsuka; Hiroaki Ikeda; Kazushi Tanimoto; Seitaro Terakura; Makoto Murata; Yoko Inaguma; Masahiro Masuya; Naoki Inoue; Tomohide Kidokoro; Sachiko Okamoto; Daisuke Tomura; Hideto Chono; Ikuei Nukaya; Junichi Mineno; Tomoki Naoe; Nobuhiko Emi; Masaki Yasukawa; Naoyuki Katayama; Hiroshi Shiku
Journal:  Blood       Date:  2017-08-31       Impact factor: 22.113

7.  Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse.

Authors:  Robson G Dossa; Tanya Cunningham; Daniel Sommermeyer; Indira Medina-Rodriguez; Melinda A Biernacki; Kimberly Foster; Marie Bleakley
Journal:  Blood       Date:  2017-10-19       Impact factor: 25.476

8.  PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.

Authors:  M H Qazilbash; E Wieder; P F Thall; X Wang; R Rios; S Lu; S Kanodia; K E Ruisaard; S A Giralt; E H Estey; J Cortes; K V Komanduri; K Clise-Dwyer; G Alatrash; Q Ma; R E Champlin; J J Molldrem
Journal:  Leukemia       Date:  2016-09-22       Impact factor: 11.528
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.